Literature DB >> 27522673

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing.

T Ruggiero1, E Burdino2, A Calcagno3, S Bonora3, L Boglione3, G Di Perri3, V Ghisetti2.   

Abstract

PURPOSE: Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce.
METHODS: NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection).
RESULTS: NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162-2.916).
CONCLUSIONS: HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

Entities:  

Keywords:  DAAs; HIV/HCV coinfected; Hepatitis C virus; RAVs

Mesh:

Substances:

Year:  2016        PMID: 27522673     DOI: 10.1007/s15010-016-0937-4

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  10 in total

Review 1.  The importance of resistance to direct antiviral drugs in HCV infection in clinical practice.

Authors:  Christoph Sarrazin
Journal:  J Hepatol       Date:  2015-09-26       Impact factor: 25.083

2.  Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV/HCV-coinfected individuals treated with antiretroviral therapy.

Authors:  Giulia Morsica; Sabrina Bagaglio; Caterina Uberti-Foppa; Laura Galli; Adriano Lazzarin
Journal:  J Acquir Immune Defic Syndr       Date:  2009-05-01       Impact factor: 3.731

3.  Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis.

Authors:  C S Graham; L R Baden; E Yu; J M Mrus; J Carnie; T Heeren; M J Koziel
Journal:  Clin Infect Dis       Date:  2001-07-06       Impact factor: 9.079

4.  Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV.

Authors:  Tânia Silva; Helena Cortes Martins; Rodrigo Coutinho; Emília Leitão; Rui Silva; Elizabeth Pádua
Journal:  J Med Virol       Date:  2015-05-01       Impact factor: 2.327

5.  Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial.

Authors:  Michael Manns; Patrick Marcellin; Fred Poordad; Evaldo Stanislau Affonso de Araujo; Maria Buti; Yves Horsmans; Ewa Janczewska; Federico Villamil; Jane Scott; Monika Peeters; Oliver Lenz; Sivi Ouwerkerk-Mahadevan; Guy De La Rosa; Ronald Kalmeijer; Rekha Sinha; Maria Beumont-Mauviel
Journal:  Lancet       Date:  2014-06-04       Impact factor: 79.321

6.  Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients.

Authors:  P Trimoulet; C Belzunce; M Faure; L Wittkop; S Reigadas; M Dupon; J-M Ragnaud; H Fleury; D Neau
Journal:  HIV Med       Date:  2011-03-16       Impact factor: 3.180

Review 7.  Hepatitis C virus drug resistance-associated substitutions: State of the art summary.

Authors:  Erik Lontok; Patrick Harrington; Anita Howe; Tara Kieffer; Johan Lennerstrand; Oliver Lenz; Fiona McPhee; Hongmei Mo; Neil Parkin; Tami Pilot-Matias; Veronica Miller
Journal:  Hepatology       Date:  2015-07-30       Impact factor: 17.425

8.  Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.

Authors:  Jean-Michel Molina; Chloe Orkin; David M Iser; Francisco-Xavier Zamora; Mark Nelson; Christoph Stephan; Benedetta Massetto; Anuj Gaggar; Liyun Ni; Evguenia Svarovskaia; Diana Brainard; G Mani Subramanian; John G McHutchison; Massimo Puoti; Jürgen K Rockstroh
Journal:  Lancet       Date:  2015-02-04       Impact factor: 79.321

9.  Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study.

Authors:  Eric Lawitz; Mark S Sulkowski; Reem Ghalib; Maribel Rodriguez-Torres; Zobair M Younossi; Ana Corregidor; Edwin DeJesus; Brian Pearlman; Mordechai Rabinovitz; Norman Gitlin; Joseph K Lim; Paul J Pockros; John D Scott; Bart Fevery; Tom Lambrecht; Sivi Ouwerkerk-Mahadevan; Katleen Callewaert; William T Symonds; Gaston Picchio; Karen L Lindsay; Maria Beumont; Ira M Jacobson
Journal:  Lancet       Date:  2014-07-28       Impact factor: 79.321

10.  Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.

Authors:  Thomas Kuntzen; Joerg Timm; Andrew Berical; Niall Lennon; Aaron M Berlin; Sarah K Young; Bongshin Lee; David Heckerman; Jonathan Carlson; Laura L Reyor; Marianna Kleyman; Cory M McMahon; Christopher Birch; Julian Schulze Zur Wiesch; Timothy Ledlie; Michael Koehrsen; Chinnappa Kodira; Andrew D Roberts; Georg M Lauer; Hugo R Rosen; Florian Bihl; Andreas Cerny; Ulrich Spengler; Zhimin Liu; Arthur Y Kim; Yanming Xing; Arne Schneidewind; Margaret A Madey; Jaquelyn F Fleckenstein; Vicki M Park; James E Galagan; Chad Nusbaum; Bruce D Walker; Gerond V Lake-Bakaar; Eric S Daar; Ira M Jacobson; Edward D Gomperts; Brian R Edlin; Sharyne M Donfield; Raymond T Chung; Andrew H Talal; Tony Marion; Bruce W Birren; Matthew R Henn; Todd M Allen
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

  10 in total
  1 in total

1.  A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome.

Authors:  Sabrina Bagaglio; Hamid Hasson; Luca Peano; Riccardo Vercesi; Emanuela Messina; Andrea Galli; Caterina Uberti Foppa; Giulia Morsica
Journal:  Viruses       Date:  2020-02-28       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.